CoChat

Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial

Open access
Jha, Manish K., Wakhlu, Shereen, Dronamraju, Neha, Minhajuddin, Abu, Greer, Tracy L., Trivedi, Madhukar H. · 2018 · Journal of Affective Disorders
Cited by 60

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action. Methods: Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants with BMI measurement (n=662) were categorized as normal- or underweight (<25), overweight (25-<30), obese I (30-<35), and obese II+ (≥35). Logistic regression analysis with remission as the dependent variable and treatment arm-by-BMI category interaction as the primary independent variable was used to evaluate if BMI differentially predicted response to escitalopram (SSRI) monotherapy, bupropion-escitalopram combination, or venlafaxine-mirtazapine combination, after controlling for gender and baseline depression severity. Results: Remission rates among the three treatment arms differed on the basis of pre-treatment BMI (chi-square=12.80, degrees of freedom=6, p=0.046). Normal- or under-weight participants were less likely to remit with the bupropion-SSRI combination (26.8%) than SSRI monotherapy (37.3%, number needed to treat or NNT=9.5) or venlafaxine-mirtazapine combination (44.4%, NNT=5.7). Conversely, obese II+ participants were more likely to remit with bupropion-SSRI (47.4%) than SSRI monotherapy (28.6%, NNT=5.3) or venlafaxine-mirtazapine combination (37.7%, NNT=10.3). Remission rates did not differ among overweight and obese I participants. Limitations: Secondary analysis, higher rates of obesity than the general population. Conclusions: Antidepressant selection in clinical practice can be personalized with BMI measurements. Bupropion-SSRI combination should be avoided in normal- or under-weight depressed outpatients as compared to SSRI monotherapy and venlafaxine-mirtazapine combination and preferred in those with BMI≥35.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jad.2018.02.089

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 60

Metadata

Authors
Jha, M. K., Wakhlu, S., Dronamraju, N., Minhajuddin, A., Greer, T. L., & Trivedi, M. H.
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2018-07
Volume
234
Pages
34-37
ISSN
0165-0327 (ISSN-L)
OpenAlex
W2789957615
Cited by
60
References
9
FWCI
4.33
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial. https://app.cochat.ai/papers/10.1016/j.jad.2018.02.089
The paper
Jha, M. K., Wakhlu, S., Dronamraju, N., Minhajuddin, A., Greer, T. L., & Trivedi, M. H. (2018). Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2018.02.089

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.